Ocular Therapeutix Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
325
- Stock Symbol
-
OCUL
- Investments
-
2
- Share Price
-
$6.21
- (As of Friday Closing)
Ocular Therapeutix General Information
Description
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Contact Information
Website
www.ocutx.comCorporate Office
- 15 Crosby Drive
- Bedford, MA 01730
- United States
Corporate Office
- 15 Crosby Drive
- Bedford, MA 01730
- United States
Ocular Therapeutix Timeline
Ocular Therapeutix Stock Performance
As of 13-Nov-2026, Ocular Therapeutix’s stock price is $6.21. Its current market cap is $1.37B with 220M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.21 | $6.28 | $6.00 - $16.44 | $1.37B | 220M | 3.1M | -$1.46 |
Ocular Therapeutix Financials Summary
As of 30-Sep-2026, Ocular Therapeutix has a trailing 12-month revenue of $50.4M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,165,196 | 2,318,632 | 990,541 | 484,648 |
| Revenue | 50,384 | 51,951 | 63,723 | 58,443 |
| EBITDA | (332,605) | (268,136) | (196,425) | (70,398) |
| Net Income | (326,811) | (265,939) | (193,506) | (80,736) |
| Total Assets | 605,647 | 808,057 | 457,935 | 252,060 |
| Total Debt | 80,013 | 76,968 | 75,783 | 83,389 |
Ocular Therapeutix Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Ocular Therapeutix Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Ocular Therapeutix Comparisons
Industry
Financing
Details
Ocular Therapeutix Competitors (6)
One of Ocular Therapeutix’s 6 competitors is Novo Nordisk, a Corporation company based in Bagsvaerd, Denmark.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novo Nordisk | Corporation | Bagsvaerd, Denmark | ||||
| Clearside Biomedical | Formerly VC-backed | Alpharetta, GA | ||||
| Mati Therapeutics | Venture Capital-Backed | Austin, TX | ||||
| TearClear | Venture Capital-Backed | Princeton, NJ | ||||
| iSTAR Medical | Formerly VC-backed | Wavre, Belgium |
Ocular Therapeutix Patents
Ocular Therapeutix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026107180-A1 | Implant injector device | Pending | 14-Nov-2024 | ||
| WO-2026080130-A1 | Ocular implant comprising an amorphous solid dispersion comprising a tyrosine kinase inhibitor and a polymer excipient | Pending | 09-Oct-2024 | ||
| AU-2025282157-A1 | Compositions and methods for treating ocular diseases | Pending | 06-Jun-2024 | ||
| WO-2025255203-A1 | Compositions and methods for treating ocular diseases | Pending | 06-Jun-2024 | ||
| WO-2025255023-A1 | Sustained release prodrug implant | Pending | 03-Jun-2024 | A61K9/0051 |
Ocular Therapeutix Signals
Ocular Therapeutix Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Ocular Therapeutix Investments & Acquisitions (2)
Ocular Therapeutix’s most recent deal was a Seed Round with Auto Legends for . The deal was made on 06-Mar-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Auto Legends | 06-Mar-2025 | Seed Round | Entertainment Software | ||
| InnFocus | 01-Mar-2023 | Merger/Acquisition | Surgical Devices |
Ocular Therapeutix ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.67 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Ocular Therapeutix Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Ocular Therapeutix Securities | Bedford, MA | 2021 |
Ocular Therapeutix FAQs
-
When was Ocular Therapeutix founded?
Ocular Therapeutix was founded in 2006.
-
Where is Ocular Therapeutix headquartered?
Ocular Therapeutix is headquartered in Bedford, MA.
-
What is the size of Ocular Therapeutix?
Ocular Therapeutix has 325 total employees.
-
What industry is Ocular Therapeutix in?
Ocular Therapeutix’s primary industry is Drug Delivery.
-
Is Ocular Therapeutix a private or public company?
Ocular Therapeutix is a Public company.
-
What is Ocular Therapeutix’s stock symbol?
The ticker symbol for Ocular Therapeutix is OCUL.
-
What is the current stock price of Ocular Therapeutix?
As of 13-Nov-2026 the stock price of Ocular Therapeutix is $6.21.
-
What is the current market cap of Ocular Therapeutix?
The current market capitalization of Ocular Therapeutix is $1.37B.
-
What is Ocular Therapeutix’s current revenue?
The trailing twelve month revenue for Ocular Therapeutix is $50.4M.
-
Who are Ocular Therapeutix’s competitors?
Novo Nordisk, Clearside Biomedical, Mati Therapeutics, TearClear, and iSTAR Medical are some of the 6 competitors of Ocular Therapeutix.
-
What is Ocular Therapeutix’s annual earnings per share (EPS)?
Ocular Therapeutix’s EPS for 12 months was -$1.46.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process